Screening


PerkinElmer


PerkinElmer is launching the first bench-top multimode


reader that incorporates the established Corning Epic®


optical label-free technology in early 2011


robotic platform. This system is well suited for secondary screening in drug discovery due to its ability to perform short-term GPCR assays as well as longer-term cytotoxicity applications in addi- tion to utilising primary cells and assessing endogenous receptors for more physiologically relevant data.


The ForteBio Octet® RED384 and Octet® QK384


Also new for 2011 is the xCELLigence™ RTCA Cardio instrument for pre-clinical safety testing of lead compounds in drug discovery. The ultra-high data capture rate of this system resolves the actual beating patterns of culture cardiomyoctyes, thus allowing for the detection of compound induced arrhythmias in real-time. “Utilising human stem cell-derived cardiomyocytes or induced pluripotent stem cell cardiomyocytes provides an earlier pre- dictive link to possible live human drug reaction and should lead to the possibility of reduced ani- mal testing and earlier identification of failed hits in the screening process,” says Hurwitz.


PerkinElmer (www.perkinelmer.com) will be launching the first bench-top multimode reader that incorporates the established Corning Epic® optical label-free technology in early 2011, accord- ing to Achim von Leoprechting, Vice-President and General Manager of Imaging and Detection Technologies, PerkinElmer, Inc. The new system is a lower cost, compact platform and, along with the label-free detection, can include classical labelled technologies such as AlphaScreen, absorbance, flu- orescence and luminescence readout modalities. “The use of optical label-free detection allows the researcher to measure biochemical and cellular events without introduction of labels and therefore minimises perturbations in the activity to be meas- ured,” says von Leoprechting. “This has particular relevance when looking at cellular activity, either in basic research or in drug discovery.” The use of label-free detection in a multimodal reader offers the researcher complete flexibility with biochemi- cal and cellular analysis. The effects of drugs as measured in classical HTS formats can be directly compared in the same instrument and on the same cells, thereby allowing for the first time direct com- parisons to be made of drug pharmacology. The system is “specifically powerful in orthogo- nal testing as part of the hit confirmation process for structure activity relationship (SAR) studies due to its exquisite sensitivity and for biophysical tests as a higher throughput front end screen, for example, for the determination of binding strength,” says von Leoprechting. “This new sys- tem would also be used as an assay development tool in disease research labs in the drug discovery process to run label-free assays on a cost-effective, flexible and compact platform. This is made possi- ble with the unique offering of multimodal func- tionality and robust proven label-free technology, at an affordable price.”


ForteBio


ForteBio, Inc (www.fortebio.com) has launched two next-generation instruments during the last two years, according to Christopher Silva, ForteBio’s Vice-President of Marketing – the Octet® RED384 for protein, peptide, small mole- cule and fragment screening and the Octet® QK384 for protein and antibody assays. The Octet® RED384 and the Octet® QK384 will enable 384-well detection, 16-channel simultane- ous readout, biosensor regeneration and reracking, and automation capabilities for biotherapeutic and pharmaceutical drug discovery assays. Recently, the company also launched two new


44 Drug Discovery World Winter 2010/11


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80